These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7538285)

  • 21. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
    Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ
    Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E; Launay D; Hatron PY
    Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
    Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.
    Marasini B; Massarotti M; Bottasso B; Coppola R; Del Papa N; Maglione W; Comina DP; Maioli C
    Scand J Rheumatol; 2004; 33(4):253-6. PubMed ID: 15370722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon.
    Watson HR; Belcher G
    Ann Rheum Dis; 1991 Jun; 50(6):359-61. PubMed ID: 1711834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects.
    Wollersheim H; Thien T; van 't Laar A
    J Clin Pharmacol; 1987 Nov; 27(11):907-13. PubMed ID: 3429697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nifedipine in the treatment of idiopathic Raynaud's syndrome.
    Sarkozi J; Bookman AA; Mahon W; Ramsay C; Detsky AS; Keystone EC
    J Rheumatol; 1986 Apr; 13(2):331-6. PubMed ID: 3723496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000954. PubMed ID: 10796396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
    Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
    Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
    Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
    Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
    Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP
    Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.